Next Article in Journal
A Shifty Target: Tumor-Initiating Cells and Their Metabolism
Next Article in Special Issue
VEGFR-1 Regulates EGF-R to Promote Proliferation in Colon Cancer Cells
Previous Article in Journal
Reduction-Triggered Paclitaxel Release Nano-Hybrid System Based on Core-Crosslinked Polymer Dots with a pH-Responsive Shell-Cleavable Colorimetric Biosensor
Previous Article in Special Issue
The Landscape of Actionable Gene Fusions in Colorectal Cancer
 
 
Review
Peer-Review Record

BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights

Int. J. Mol. Sci. 2019, 20(21), 5369; https://doi.org/10.3390/ijms20215369
by Francesco Caputo 1,†, Chiara Santini 1,†, Camilla Bardasi 1, Krisida Cerma 1, Andrea Casadei-Gardini 1,*, Andrea Spallanzani 1, Kalliopi Andrikou 1, Stefano Cascinu 1,2 and Fabio Gelsomino 1
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2019, 20(21), 5369; https://doi.org/10.3390/ijms20215369
Submission received: 15 October 2019 / Revised: 23 October 2019 / Accepted: 24 October 2019 / Published: 28 October 2019
(This article belongs to the Special Issue Molecular and Translational Research on Colorectal Cancer)

Round 1

Reviewer 1 Report

This is a comprehensive review on BRAF mutation (V600E) in colorectal cancers (CRC) which is observed in ~10% of CRC cases, and how it affects prognosis and treatment with various monoclonal antibodies (Bevazizumab) and inhibitors (FOLFOXIRI).  The authors also discussed in detail about the BEACON trial (BRAF/MEK combination therapy) used in CRC treatment.  The review provides detailed information on patient resistance to standard treatment of BRAF-mutated CRC, with a focus on molecular heterogeneity and on research perspectives on translational and clinical aspects.     

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

The authors reviewed the heterogeneity of BRAF mutated CRC. They discussed the mechanisms for resistance of BRAFi, current clinic trials, and future therapeutic directions. There are a few minor concerns:

The title may need to be changed as it is somewhat misleading. Essentially the authors just want to emphasize the tumor heterogeneity, which is applicable to any kind of tumor. Line 48 and 83 are duplicate as they are talking about the same thing: BRAF mutation is found in about 10% mCRC. Line 108, please define “cycle 20 checkpoint associated genes”? For the BEACON study, it should be moved to the “Triplet combinations” section and table 1. The discussion about Ref 82 should also be moved to the “Triplet combinations” section. The significance of this study may need to be further explained as studies such as ref 74/75/77 are all have comparable or even better efficacy. Is the large cohort make it distinct?

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Back to TopTop